RxDoctor Payments Data

Belinda Maples, MD

Family Medicine · Athens, ALNPI 1245223684

Payments from drug & device makers

$6,535in general payments, 2019–2025

Across 413 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$919
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
  • AstraZeneca$404
  • GSK$395
  • Lilly USA, LLC$373
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,43598%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,535 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$105,144
Medicare patients
280
Services billed
2,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$151,555
FarxigaDapagliflozin Propanediol169$139,366
RybelsusSemaglutide79$125,562
MounjaroTirzepatide89$104,088
OzempicSemaglutide67$83,157
TrulicityDulaglutide57$72,234
EntrestoSacubitril/Valsartan77$66,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$56,119
JardianceEmpagliflozin56$42,856
Xigduo XrDapaglifloz Propaned/Metformin40$32,092
ProliaDenosumab19$32,039
Bydureon BciseExenatide Microspheres22$31,817
XareltoRivaroxaban31$29,465
Tresiba Flextouch U-100Insulin Degludec33$25,534
MyrbetriqMirabegron18$22,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$919$208,719146 claims
Lilly USA, LLCMounjaro, Trulicity$373$176,322146 claims
PfizerEliquis, Abrysvo$372$159,897181 claims
AstraZenecaFarxiga, Symbicort$404$148,418187 claims
NovartisEntresto$240$66,27477 claims
GSKTrelegy Ellipta$395$56,11961 claims
AmgenProlia$91$32,03919 claims
Johnson & JohnsonXarelto$134$29,46531 claims
MerckJanuvia, Belsomra$40$27,04533 claims
Astellas Pharma US IncMyrbetriq$224$22,00318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →